文献速递造血干细胞移植与细胞治疗

人绒毛膜促性腺激素与表皮生长因子促进危及生命的急性移植物抗宿主病缓解

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor.
PubMed 文献 · Blood Adv · 2020-01-01

这项1期研究纳入26例异基因造血细胞移植后急性移植物抗宿主病(aGVHD)患者,在标准免疫抑制基础上加用尿源性人绒毛膜促性腺激素(uhCG)皮下注射,其中13例高危aGVHD接受初始治疗、13例接受二线治疗。uhCG耐受良好,无剂量限制性毒性;高危组62%、二线组54%的患者在第28天达完全缓解,高危组给药后6小时血浆表皮生长因子(EGF)升高六倍(从4至24 pg/mL;P = .02)。

要点

  • uhCG联合标准免疫抑制耐受良好,未观察到剂量限制性毒性。
  • 第28天完全缓解率:高危组62%,二线组54%。
  • 高危组给药后6小时血浆EGF由4升至24 pg/mL(P = .02),二线组未见EGF峰值。

核心结论

  • uhCG是一种新型、安全的支持性疗法,研究者在高危aGVHD中以2000 units/m2进入2期试验。

研究设计与样本

  • 1期研究纳入26例受试者,在标准免疫抑制基础上加用uhCG皮下注射,其中13例按Minnesota标准接受高危aGVHD初始治疗、13例接受二线治疗。
  • 研究期间对受试者进行系列血液检测,评估激素反应、免疫调节和aGVHD活动的生物标志物。
  • 本研究在www.clinicaltrials.gov注册,注册号为#NCT02525029。

主要发现

  • uhCG耐受良好,无剂量限制性毒性。
  • 高危队列62%的患者、二线队列54%的患者在研究第28天达完全缓解。
  • 高危队列给药后6小时血浆EGF升高六倍(从4至24 pg/mL;P = .02),而更严重的二线队列血浆EGF未见峰值。
  • uhCG治疗1周后,患者报告调节性T细胞与传统T细胞比值升高两倍,提示尽管使用大剂量类固醇仍存在免疫调节。
  • 缓解患者在研究完成时报告血浆双调蛋白较低、血浆丁酸水平较高,提示黏膜损伤随时间改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is a potentially fatal complication of allogeneic hematopoietic cell transplantation that fails to improve with intense immunosuppression in some patients. We hypothesized that urinary-derived human chorionic gonadotropin (uhCG) could help facilitate resolution of life-threatening aGVHD when added as supportive care via 2 potential mechanisms: immunomodulation (akin to its role in pregnancy) and supplementation of epidermal growth factor (EGF; to aid in epithelial repair). In a phase 1 study, 26 participants received subcutaneous injections of uhCG in addition to standard immunosuppression (13 receiving initial therapy for high-risk aGVHD [according to the Minnesota criteria] and 13 receiving second-line therapy). Participants underwent serial blood testing for biomarkers of hormone response, immune modulation, and aGVHD activity on study. uhCG was well tolerated, with no dose-limiting toxicities. Sixty-two percent of patients in the high-risk cohort and 54% of patients in the second-line cohort had a complete response at study day 28. Plasma EGF was elevated sixfold (from 4 to 24 pg/mL; P = .02) at 6 hours postdose in the high-risk cohort, in contrast to no peak in plasma EGF in the more severe second-line cohort. After 1 week of uhCG, patients reported a twofold increase in the regulatory T cell to conventional T-cell ratio, suggesting immune modulation despite high-dose steroids. Responding patients reported significantly lower plasma amphiregulin and higher plasma butyrate levels at study completion, suggesting improvement in mucosal damage over time. uhCG is a novel, safe, supportive therapy, proceeding to phase 2 testing at 2000 units/m2 in high-risk aGVHD. This study was registered at www.clinicaltrials.gov as #NCT02525029.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Holtan SG, Hoeschen AL, Cao Q, et al. Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Adv. 2020. PMID: 32236525. doi:10.1182/bloodadvances.2019001259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。